Interstitial Lung Disease (ILD) Clinical Trials

Interventional Studies

MIND-ILD

  • A randomized, clinical study investigating a wellness-based intervention for patients with newly diagnosed Interstitial Lung Disease
  • Contact: Christopher Depender; cd2686@cumc.columbia.edu
  • Principal Investigator: Christine Kim Garcia, MD, PhD
  • Start Date: September 2020
  • End Date: September 2022

Non-Interventional (Observational) Studies

COVID-ILD

  • A prospective cohort study designed to study the presence of pulmonary fibrosis in survivors of severe COVID-19. Individuals who had a positive SARS-CoV-2 nasal swab, who were hospitalized, and who required supplemental oxygen while hospitalized are eligible to participate.   
  • Contact: Atif Choudhury; mac2463@cumc.columbia.edu
  • Principal Investigator: Christine K. Garcia MD, PhD
  • Start Date: 8/1/2020
  • End Date: 12/31/2024

FAR-ILD

  • A prospective cohort study designed to detect and study the earliest stages of ILD in at-risk adults. The purpose of FAR-ILD is to gather data on adults at risk for developing ILD over a long period of time in order to help physicians and investigators better understand interstitial lung disease.
  • Contact: Atif Choudhury; mac2463@cumc.columbia.edu
  • Principal Investigator: Christine K. Garcia MD, PhD
  • Start Date: 8/1/2020
  • End Date: 12/31/2024
  • https://recruit.cumc.columbia.edu/clinical_trial/1932

INBUILD-ON

  • An open label extension of the INBUILD clinical trial, which was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD), PF-ILD defined as patients who present with features of diffuse fibrosing lung disease of >10% extent on high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment with unapproved medications used in clinical practice to treat ILD.
  • Contact: Atif Choudhury; mac2463@cumc.columbia.edu
  • Principal Investigator: David Zhang, MD
  • Start Date: Jan 1, 2017
  • End Date: Open label extension ongoing
  • ClinicalTrials.gov: NCT02999178

SENSCIS-ON

  • An open label extension of the SENSCIS clinical trial, which was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD).
  • Contact: Atif Choudhury; mac2463@cumc.columbia.edu
  • Principal Investigator: David Zhang, MD
  • Start Date:  November 12, 2005
  • End Date: Study completed November 28, 2018; open label extension ongoing
  • ClinicalTrials.gov: NCT02597933

Registry Studies

Molecular Basis of Cardiopulmonary Disorders

  • A prospective cohort study designed to identify genetic causes of heart and lung diseases and to develop a repository to better understand, prevent and treat these conditions. Individuals may be asked to donate a sample of blood, a skin sample, or cells/tissue removed as part of medical care.
  • Contact: Christopher Depender; cd2686@cumc.columbia.edu
  • Principal Investigator: Christine Kim Garcia, MD, PhD
  • Start Date: December 2018
  • End Date: Ongoing
  • https://recruit.cumc.columbia.edu/clinical_trial/1829

Precision Medicine Approach to Lung Disease

  • A collaborative approach to identify genetic causes of lung diseases and to develop a repository to better understand, prevent, and treat these conditions. Members of study group include specialists from the Division of Pulmonary, Allergy, and Critical Care Medicine at Columbia University Irving Medical Center.
  • Contact: Christopher Depender; cd2686@cumc.columbia.edu
  • Principal Investigator: Christine Kim Garcia, MD, PhD, on behalf of the multi-investigator study group
  • Start Date: October 2019
  • End Date: Ongoing
  • https://recruit.cumc.columbia.edu/clinical_trial/1830

Pulmonary Fibrosis Foundation (PFF) Registry

  • People living with PF who choose to enroll in the registry share detailed medical information that will be used for research. The registry contains information about how each person’s diagnosis was made, symptoms from PF, medical test results, the use of medications used to treat PF, and even captures information about how people are doing years after enrolling.
  • Contact: Atif Choudhury; mac2463@cumc.columbia.edu
  • Principal Investigator: Christine Kim Garcia, MD, PhD
  • Start Date: March 2016
  • End Date: March 2021
  • https://www.pulmonaryfibrosis.org/medical-community/pff-patient-registry

IPF/ILD-PRO

  • This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease (ILD) and the treatment and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient-reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.
  • Contact: Atif Choudhury; mac2463@cumc.columbia.edu
  • Principal Investigator: David Zhang, MD
  • Start Date: June 2014
  • End Date: January 2025
  • ClinicalTrials.gov: NCT01915511